Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercalcemia of malignancy.

Jean-Jacques Body1

  • 1Supportive Care Clinic and Clinic of Endocrinlogy and Bone Disease, Université Libre de Bruxelles, Belgium. jj.body@bordet.be

Seminars in Nephrology
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult Males.

Clinical and translational science·2026
Same author

Association between sarcopenia, its components, and osteoporosis in the FRISBEE cohort.

BMC musculoskeletal disorders·2025
Same author

Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926].

Clinical therapeutics·2025
Same author

Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.

Journal of bone oncology·2025
Same author

Osteosarcopenia, sarcopenia, and their associations with validated recent fragility fractures in older women: applying seven definitions in the FRISBEE 2 study.

European geriatric medicine·2025
Same author

Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2025
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Tumor-induced hypercalcemia is now treatable in over 90% of cases using bisphosphonates, potent anti-osteoclastic drugs. These treatments significantly reduce hypercalcemia incidence, improving cancer patient outcomes.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Tumor-induced hypercalcemia was a frequently lethal cancer complication.
  • Modern treatments have dramatically improved outcomes, achieving success in over 90% of cases.
  • Bisphosphonates are key therapeutic agents due to their potent anti-osteoclastic activity.

Purpose of the Study:

  • To review the current therapeutic strategies for tumor-induced hypercalcemia.
  • To highlight the efficacy of bisphosphonates in managing and preventing hypercalcemia.
  • To discuss potential future treatments for refractory cases.

Main Methods:

  • Review of current clinical practices and therapeutic guidelines.
  • Analysis of bisphosphonate efficacy in managing hypercalcemia.

Related Experiment Videos

  • Discussion of novel therapeutic approaches, including antibody therapies.

    • Main Results:

    • Bisphosphonates, such as pamidronate and zoledronic acid, are highly effective in treating hypercalcemia.
    • Long-term bisphosphonate therapy significantly reduces the incidence of hypercalcemic episodes.
    • Antibodies targeting parathyroid hormone-related protein show promise for specific patient groups.

    Conclusions:

    • Tumor-induced hypercalcemia is now a manageable complication with current therapies.
    • Bisphosphonates are the cornerstone of treatment and prevention, significantly reducing disease incidence.
    • Further research into novel agents is warranted for recurrent or refractory hypercalcemia.